Skip to main content
SpringerLink
Log in
Book cover

Apoptosis, Senescence, and Cancer pp 299–312Cite as

Ceramide and Multidrug Resistance

  • Chapter

  • 1680 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

summary

Chemotherapy resistance represents a formidable barrier to the successful treatment of advancing cancer, and patients and oncologists would welcome its possible correction. Unfortunately, many frontline chemotherapeutic agents drive biochemical events that promote tumor cell resistance. Averting these events is key to halting and perhaps reversing this process. Only recently have we begun to appreciate the role of lipids in both chemotherapy response mechanisms and resistance process. Because much emphasis is being placed on “targeted therapeutics,” we believe that targeting the enzymes of lipid metabolism represents a promising direction in the treatment of cancer. This chapter explains how the harnessing of ceramide metabolism could be key in tempering multidrug resistance.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Morton DL, Essner R, Kirkwood JM, Wollman RC. Malignant melanoma. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, Eds. Cancer Medicine. Sixth edition. BC Decker, Ontario, Canada, 2003:1973–1995.

    Google Scholar 

  2. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615–627.

    PubMed  CAS  Google Scholar 

  3. Sikic BI. Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology (Williston Park) 1999;13:183–187.

    CAS  Google Scholar 

  4. Kourousis C, Kakolyris S, Androulakis N, Heras P, Vlachonicolis J, Vamvakas L, Vlata M, Hatzidaki D, Samonis G, Georgoulias V. Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. Am J Clin Oncol 1998;21: 226–232.

    PubMed  CAS  Google Scholar 

  5. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999;9:51–58.

    PubMed  CAS  Google Scholar 

  6. Mirski SE, Cole SP. Multidrug resistance in small cell lung cancer. In: Bernal SD, Ed. Drug Resistance in Oncology. Marcel Dekker, New York, 1997:27–77.

    Google Scholar 

  7. Mouton RE, Venable ME. Ceramide induces expression of the senescence histochemical marker, beta-galactosidase, in human fibroblasts. Mech Ageing Dev 2000;113:169–181.

    PubMed  CAS  Google Scholar 

  8. DeJesus V, Rios I, Davis C, Chen Y, Calhoun D, Zakeri Z, Hubbard K. Induction of apoptosis in human replicative senescent fibroblasts. Exp Cell Res 2002;274:92–99.

    PubMed  CAS  Google Scholar 

  9. Hampel B, Malisan F, Niederegger H, Testi R, Jansen-Durr P. Differential regulation of apoptotic cell death in senescent human cells. Exp Gerontol 2004;39:1713–1721.

    PubMed  CAS  Google Scholar 

  10. Lee JY, Bielawska AE, Obeid LM. Regulation of cyclin-dependent kinase 2 activity by ceramide. Exp Cell Res 2000;261:303–311.

    PubMed  CAS  Google Scholar 

  11. DeMasters GA, Gupta MS, Jones KR, Cabot M, Wang H, Gennings C, Park M, Bratland A, Ree AH, Gewirtz DA. Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089. J Steroid Biochem Mol Biol 2004;92:365–374.

    PubMed  CAS  Google Scholar 

  12. Venable ME, Webb-Froehlich LM, Sloan EF, Thomley JE. Shift in sphingolipid metabolism leads to an accumulation of ceramide in senescence. Mech Ageing Dev 2006;127:473–480.

    PubMed  CAS  Google Scholar 

  13. Perez GI, Jurisicova A, Matikainen T, Moriyama T, Kim MR, Takai Y, Pru JK, Kolesnick RN, Tilly JL. A central role for ceramide in the age-related acceleration of apoptosis in the female germline. FASEB J 2005;19:860–862.

    PubMed  CAS  Google Scholar 

  14. Ruvolo PP. Ceramide regulates cellular homeostasis via diverse stress signaling pathways. Leukemia 2001;15:1153–1160.

    PubMed  CAS  Google Scholar 

  15. Ruolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 2003;47:383–392.

    Google Scholar 

  16. Chalfant CE, Kishikawa K, Mumby MC, Kamibayashi C, Bielawska A, Hannun YA. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem 1999;274:20313–20317.

    PubMed  CAS  Google Scholar 

  17. Chiang CS, Kanies C, Kim KW, Fang WB, Parkhurst C, Xie M, Henry T, Yang E. Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol Cell Biol 2003;23:6350–6362.

    PubMed  CAS  Google Scholar 

  18. Xin M, Deng X. Protein phosphatase 2A enhances Bax’s proapoptotic function through dephosphorylation. J Biol Chem 2006;281:18859–18867.

    PubMed  CAS  Google Scholar 

  19. Yellaturu CR, Bhanoori M, Neeli I, Rao GN. N-Ethylmaleimide inhibits platelet-derived growth factor BB-stimulated Akt phosphorylation via activation of protein phosphatase 2A. J Biol Chem 2002;277:40148–40155.

    PubMed  CAS  Google Scholar 

  20. Ruvolo PP, Deng X, Ito T, Carr BK, May WS. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J Biol Chem 1999;274:20296–20300.

    PubMed  CAS  Google Scholar 

  21. Zhang Y, Yao B, Delikat S, Bayoumy S, Lin XH, Basu S, McGinley M, Chan-Hui PY, Lichenstein H, Kolesnick R. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 1997;89:63–72.

    PubMed  CAS  Google Scholar 

  22. Yao B, Zhang Y, Delikat S, Mathias S, Basu S, Kolesnick R. Phosphorylation of Raf by ceramide-activated protein kinase. Nature 1995;378:307–310.

    PubMed  CAS  Google Scholar 

  23. Kajimoto T, Shirai Y, Sakai N, Yamamoto T, Matsuzaki H, Kikkawa U, Saito N. Ceramide-induced apoptosis by translocation, phosphorylation, and activation of protein kinase Cdelta in the Golgi complex. J Biol Chem 2004;279:12668–12676.

    PubMed  CAS  Google Scholar 

  24. Aschrafi A, Franzen R, Shabahang S, Fabbro D, Pfeilschifter J, Huwiler A. Ceramide induces translocation of protein kinase C-alpha to the Golgi compartment of human embryonic kidney cells by interacting with the C2 domain. Biochim Biophys Acta 2003;1634:30–39.

    PubMed  CAS  Google Scholar 

  25. Kashiwagi K, Shirai Y, Kuriyama M, Sakai N, Saito N. Importance of C1B domain for lipid messenger-induced targeting of protein kinase C. J Biol Chem 2002;277:18037–18045.

    PubMed  CAS  Google Scholar 

  26. Becker KP, Kitatani K, Idkowiak-Baldys J, Bielawski J, Hannun YA. Selective inhibition of juxtanuclear translocation of protein kinase C betaII by a negative feedback mechanism involving ceramide formed from the salvage pathway. J Biol Chem 2005;280:2606–2612.

    PubMed  CAS  Google Scholar 

  27. Becker KP, Hannun YA. cPKC-dependent sequestration of membrane-recycling components in a subset of recycling endosomes. J Biol Chem 2003;278:52747–52754.

    PubMed  CAS  Google Scholar 

  28. Wang G, Silva J, Krishnamurthy K, Tran E, Condie BG, Bieberich E. Direct binding to ceramide activates protein kinase Czeta before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J Biol Chem 2005;280:26415–26424.

    PubMed  CAS  Google Scholar 

  29. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism–a strategy for overcoming drug resistance. J Natl Cancer Inst 2001;93:347–357.

    PubMed  CAS  Google Scholar 

  30. Spiegel S, Foster D, Kolesnick R. Signal transduction through lipid second messengers. Curr Opin Cell Biol 1996;8:159–167.

    PubMed  CAS  Google Scholar 

  31. Merrill AH Jr, Schmelz EM, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ, Riley RT, Voss KA, Wang E. Sphingolipids–the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol 1997;142:208–225.

    PubMed  CAS  Google Scholar 

  32. Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J 1998;335:465–480.

    PubMed  CAS  Google Scholar 

  33. Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry 2001;40:4893–4903.

    PubMed  CAS  Google Scholar 

  34. Wang H, Maurer BJ, Reynolds CP, Cabot MC. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 2001;61:5102–5105.

    PubMed  CAS  Google Scholar 

  35. Lovat PE, Di Sano F, Corazzari M, Fazi B, Donnorso RP, Pearson AD, Hall AG, Redfern CP, Piacentini M. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst 2004;96:1288–1299.

    PubMed  CAS  Google Scholar 

  36. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1995;82:405–414.

    PubMed  CAS  Google Scholar 

  37. Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int J Oncol 1999;15:541–546.

    PubMed  CAS  Google Scholar 

  38. Jaffrezou JP, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, Vermeersch S, Rousse A, Laurent G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 1996;15:2417–2424.

    PubMed  CAS  Google Scholar 

  39. Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N, Ghidoni R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J 2003;17:2339–2341.

    PubMed  CAS  Google Scholar 

  40. Perry DK, Carton J, Shah AK, Meredith F, Uhlinger DJ, Hannun YA. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J Biol Chem 2000;275:9078–9084.

    PubMed  CAS  Google Scholar 

  41. Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Muller S, Jaffrezou JP, Laurent G. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004;104:1166–1173.

    PubMed  CAS  Google Scholar 

  42. Hannun YA, Obeid LM. Mechanisms of ceramide-mediated apoptosis. Adv Exp Med Biol 1997;407: 145–149.

    PubMed  CAS  Google Scholar 

  43. Jaffrezou JP, Laurent G, Levade T. Ceramide in regulation of apoptosis. Implication in multitoxicant resistance. Subcell Biochem 2002;36:269–284.

    PubMed  CAS  Google Scholar 

  44. Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 2003;47:383–392.

    PubMed  CAS  Google Scholar 

  45. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004;206:169–180.

    PubMed  CAS  Google Scholar 

  46. Radin NS. Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem J 2003;371:243–256.

    PubMed  CAS  Google Scholar 

  47. Radin NS. Poly-drug cancer therapy based on ceramide. Eksp Onkol 2004;26:3–10.

    PubMed  CAS  Google Scholar 

  48. Kok JW, Sietsma H. Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr Drug Targets 2004;5:375–382.

    PubMed  CAS  Google Scholar 

  49. Bernal SD, Ed. Drug Resistance in Oncology. Marcel Dekker, New York, 1997.

    Google Scholar 

  50. Kellen JA, Ed. Alternative mechanisms of multidrug resistance in cancer. Birkhaüser, Boston, MA, 1995.

    Google Scholar 

  51. Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993;53:3658–3661.

    PubMed  CAS  Google Scholar 

  52. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989;49: 58–62.

    PubMed  CAS  Google Scholar 

  53. Morrow CS, Cowan KH. Glutathione S-transferases and drug resistance. Cancer Cells 1990;2: 15–22.

    PubMed  CAS  Google Scholar 

  54. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995;7:541–546.

    PubMed  CAS  Google Scholar 

  55. Mueller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 1996;16:3845–3848.

    PubMed  CAS  Google Scholar 

  56. Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 1998;273:8971–8974.

    PubMed  CAS  Google Scholar 

  57. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 1998;273:32380–32383.

    PubMed  CAS  Google Scholar 

  58. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 1996;271:19530–19536.

    PubMed  CAS  Google Scholar 

  59. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot MC. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 1998;18:475–480.

    PubMed  CAS  Google Scholar 

  60. Cai Z, Bettaieb A, Mahdani NE, Legres LG, Stancou R, Masliah J, Chouaib S. Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity. J Biol Chem 1997;272:6918–6926.

    PubMed  CAS  Google Scholar 

  61. Liu YY, Han TY, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999;274:1140–1146.

    PubMed  CAS  Google Scholar 

  62. Liu YY, Han TY, Giuliano AE, Ichikawa S, Hirabayashi Y, Cabot MC. Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-alpha-induced apoptosis. Exp Cell Res 1999;252:464–470.

    PubMed  CAS  Google Scholar 

  63. Sietsma H, Veldman RJ, Kok JW. The involvement of sphingolipids in multidrug resistance. J Membr Biol 2001;181:153–162.

    PubMed  CAS  Google Scholar 

  64. Morjani H, Aouali N, Belhoussine R, Veldman RJ, Levade T, Manfait M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int J Cancer 2001;94:157–165.

    PubMed  CAS  Google Scholar 

  65. Veldman RJ, Klappe K, Hinrichs J, Hummel I, van der Schaaf G, Sietsma H, Kok JW. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J 2002;16:1111–1113.

    PubMed  CAS  Google Scholar 

  66. Prinetti A, Basso L, Appierto V, Villani MG, Valsecchi M, Loberto N, Prioni S, Chigorno V, Cavadini E, Formelli F, Sonnino S. Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J Biol Chem 2003;278:5574–5583.

    PubMed  CAS  Google Scholar 

  67. Itoh M, Kitano T, Watanabe M, Kondo T, Yabu T, Taguchi Y, Iwai K, Tashima M, Uchiyama T, Okazaki T. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 2003;9:415–423.

    PubMed  CAS  Google Scholar 

  68. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001;15:719–730.

    PubMed  CAS  Google Scholar 

  69. Gouaze V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE, Cabot MC. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 2004;3:633–639.

    PubMed  CAS  Google Scholar 

  70. Kohno K, Sato S, Takano H, Matsuo K, Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 1989;165:break 1415–1421.

    Google Scholar 

  71. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632–639.

    PubMed  CAS  Google Scholar 

  72. Klappe K, Hinrichs JW, Kroesen BJ, Sietsma H, Kok JW. MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer 2004;110:511–522.

    PubMed  CAS  Google Scholar 

  73. Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem 2000;275:7138–7143.

    PubMed  CAS  Google Scholar 

  74. Liu YY, Cabot MC. Development of a mammalian Tet-on expression cell line: glucosylceramide synthase regulates TNF-alpha-induced apoptosis. Methods Mol Biol 2004;249:177–192.

    PubMed  CAS  Google Scholar 

  75. Pena LA, Fuks Z, Kolesnick R. Stress-induced apoptosis and the sphingomyelin pathway. Biochem Pharmacol 1997;53:615–621.

    PubMed  CAS  Google Scholar 

  76. Di Sano F, Di Bartolomeo S, Fazi B, Fiorentini C, Matarrese P, Spinedi A, Piacentini M. Antisense to glucosylceramide synthase in human neuroepithelioma affects cell growth but not apoptosis. Cell Death Differ 2002;9:693–695.

    PubMed  Google Scholar 

  77. Deng W, Li R, Guerrera M, Liu Y, Ladisch S. Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation. Glycobiology 2002;12:145–152.

    PubMed  CAS  Google Scholar 

  78. Liu YY, Han TY, Yu JY, Bitterman A, Le A, Giuliano AE, Cabot MC. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J Lipid Res 2004;45:933–940.

    PubMed  CAS  Google Scholar 

  79. Abe A, Inokuchi J, Jimbo M, Shimeno H, Nagamatsu A, Shayman JA, Shukla GS, Radin NS. Improved inhibitors of glucosylceramide synthase. J Biochem (Tokyo) 1992;111:191–196.

    CAS  Google Scholar 

  80. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE, Cabot MC. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 1997;272:1682–1687.

    PubMed  CAS  Google Scholar 

  81. Sietsma H, Veldman RJ, Kolk D, Ausema B, Nijhof W, Kamps W, Vellenga E, Kok JW. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin Cancer Res 2000;6:942–948.

    PubMed  CAS  Google Scholar 

  82. Olshefski RS, Ladisch S. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int J Cancer 2001;93:131–138.

    PubMed  CAS  Google Scholar 

  83. Nicholson KM, Quinn DM, Kellett GL, Warr JR. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br J Cancer 1999;81:423–430.

    PubMed  CAS  Google Scholar 

  84. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000;92:1897–1909.

    PubMed  CAS  Google Scholar 

  85. Alphonse G, Bionda C, Aloy MT, Ardail D, Rousson R, Rodriguez-Lafrasse C. Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene 2004;23:2703–2715.

    PubMed  CAS  Google Scholar 

  86. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003;22:5897–5906.

    PubMed  CAS  Google Scholar 

  87. Norris-Cervetto E, Callaghan R, Platt FM, Dwek RA, Butters TD. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. J Biol Chem 2004;279: 40412–40418.

    PubMed  CAS  Google Scholar 

  88. Veldman RJ, Mita A, Cuvillier O, Garcia V, Klappe K, Medin JA, Campbell JD, Carpentier S, Kok JW, Levade T. The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J 2003;17:1144–1146.

    PubMed  CAS  Google Scholar 

  89. Murate T, Suzuki M, Hattori M, Takagi A, Kojima T, Tanizawa T, Asano H, Hotta T, Saito H, Yoshida S, Tamiya-Koizumi K. Up-regulation of acid sphingomyelinase during retinoic acid-induced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line. J Biol Chem 2002;277:9936–9943.

    PubMed  CAS  Google Scholar 

  90. Kim WH, Kang KH, Kim MY, Choi KH. Induction of p53-independent p21 during ceramide-induced G1 arrest in human hepatocarcinoma cells. Biochem Cell Biol 2000;78(2):127–135.

    PubMed  CAS  Google Scholar 

  91. Chen CC, Sun YT, Chen JJ, Chang YJ. Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol 2001;59:493–500.

    PubMed  CAS  Google Scholar 

  92. Park IN, Cho IJ, Kim SG. Ceramide negatively regulates glutathione S-transferase gene transactivation via repression of hepatic nuclear factor-1 that is degraded by the ubiquitin proteasome system. Mol Pharmacol 2004;65:1475–1484.

    PubMed  CAS  Google Scholar 

  93. Abe A, Radin NS, Shayman JA. Induction of glucosylceramide synthase by synthase inhibitors and ceramide. Biochim Biophys Acta 1996;1299:333–341.

    PubMed  Google Scholar 

  94. Komori H, Ichikawa S, Hirabayashi Y, Ito M. Regulation of UDP-glucose:ceramide glucosyltransferase-1 by ceramide. FEBS Lett 2000;475:247–250.

    PubMed  CAS  Google Scholar 

  95. Ichikawa S, Ozawa K, Hirabayashi Y. Molecular cloning and characterization of the mouse ceramide glucosyltransferase gene. Biochem Biophys Res Commun 1998;253:707–711.

    PubMed  CAS  Google Scholar 

  96. Liu YY, Yu JY, Gouaze V, Hansen N, Giuliano AE, Hirabayashi Y, Cabot MC. Doxorubicin drives drug resistance in breast cancer cells through ceramide-upregulated gene expression. Proc Am Assoc Cancer Res 2003;44:847 [Abst #3703].

    Google Scholar 

  97. Plo I, Lehne G, Beckstrom KJ, Maestre N, Bettaieb A, Laurent G, Lautier D. Influence of ceramide metabolism on P-glycoprotein function in immature acute myeloid leukemia KG1a cells. Mol Pharmacol 2002;62:304–312.

    PubMed  CAS  Google Scholar 

  98. Gouaze V, Liu Y-Y, Yu JY, Prickett CS, Giuliano AE, Cabot MC. Blockers of glycolipid metabolism diminish expression of the multidrug resistance gene (MDR1) and enhance chemotherapy sensitivity (abstract). FASEB J 2004;18:C51.

    Google Scholar 

  99. Cabot MC, Giuliano AE, Volner A, Han TY. Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett 1996;394:129–131.

    PubMed  CAS  Google Scholar 

  100. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998;4:389–398.

    PubMed  CAS  Google Scholar 

  101. Yuan Y, Wang L, Zhang J. [Modulation of multidrug resistance by 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol in SKOV3-adriamycin-resistant cell line]. Zhonghua Fu Chan Ke Za Zhi 2001;36:493–495 [Chinese].

    PubMed  CAS  Google Scholar 

  102. Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 1987;262:2166–2170.

    PubMed  CAS  Google Scholar 

  103. Muller C, Goubin F, Ferrandis E, Cornil-Scharwtz I, Bailly JD, Bordier C, Benard J, Sikic BI, Laurent G. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells. Mol Pharmacol 1995;47:51–56.

    PubMed  CAS  Google Scholar 

  104. Yang Q, Zhang J, Wang SM, Zhang JR. [Expression of glucosylceramide synthase mRNA in vincristine-resistant KBV200 cell line in association with multidrug resistance]. Di Yi Jun Yi Da Xue Xue Bao 2004;24:779–781 [Chinese].

    PubMed  Google Scholar 

  105. Nohara K, Wang F, Spiegel S. Glycosphingolipid composition of MDA-MB-231 and MCF-7 human breast cancer cell lines. Breast Cancer Res Treat 1998;48:149–157.

    PubMed  CAS  Google Scholar 

  106. Kato T, Wang Y, Yamaguchi K, Milner CM, Shineha R, Satomi S, Miyagi T. Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells. Int J Cancer 2001;92:797–804.

    PubMed  CAS  Google Scholar 

  107. Fukumoto H, Nishio K, Ohta S, Hanai N, Fukuoka K, Ohe Y, Sugihara K, Kodama T, Saijo N. Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo. Int J Cancer 1999;82:759–764.

    PubMed  CAS  Google Scholar 

  108. Mazzoni A, Trave F, Fabbri M, Leto G, Ghidoni R. Membrane gangliosides and immuno-mediated cytolysis in drug sensitive and treatment-induced multidrug resistant human ovarian cancer cells. Anticancer Res 1991;11:2181–2185.

    PubMed  CAS  Google Scholar 

  109. Fukumoto H, Nishio K, Ohta S, Hanai N, Saijo N. Reversal of adriamycin resistance with chimeric anti-ganglioside GM2 antibody. Int J Cancer 1996;67:676–680.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Myles C. Cabot PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology and Toxicology and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA

    David A. Gewirtz

  2. Departments of Medicine, Pharmacology and Toxicology, Biochemistry and Massey Cancer Center, Virginia Commonwealth, Richmond, VA

    Shawn E. Holt

  3. Departments of Pathology, Human Genetics, Pharmacology and Toxicology, Biochemistry and Massey Cancer Center, Virginia Commonwealth, Richmond, VA

    Steven Grant

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this chapter

Cite this chapter

Cabot, M.C. (2007). Ceramide and Multidrug Resistance. In: Gewirtz, D.A., Holt, S.E., Grant, S. (eds) Apoptosis, Senescence, and Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-221-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-221-2_16

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-527-9

  • Online ISBN: 978-1-59745-221-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation